CONTRIBUTION OF EDN1 AND COMT GENE VARIATIONS TO THE DEVELOPMENT OF CARDIOTOXIC COMPLICATIONS

Abstract

Cardiac complications remain one of the leading causes of poor prognosis and decreased quality of life in patients receiving anticancer and combination therapy. Despite the active implementation of cardioprotective strategies, individual myocardial sensitivity to damaging factors varies significantly, indicating the significant role of genetic determinants in the development of cardiotoxicity. In recent years, increasing attention has been paid to the study of gene polymorphisms involved in the regulation of vascular tone, oxidative stress, and neurohumoral activity.